Abstract
Objective
To explore the associations between the use of the MediEmo smartphone application and IVF live birth and treatment return rates.
Design
A three-year observational cohort study
Subjects
Patients undergoing IVF were classified as users if they used the medication or emotion features of the MediEmo. Patients who did not use the two key features or declined to use the app were classified as non-users.
Exposure
The use of the MediEmo smartphone application.
Main outcome measures
Outcomes of interest were rate of live birth per fresh index cycle, live birth per complete cycle and treatment return for a stimulated cycle of treatment within 12 months of the unsuccessful stimulated index cycle.
Results
A total 1081 patients were eligible to use MediEmo app, 863 were categorised as users and 218 as non-users. MediEmo use was associated with a higher live birth rate per index cycle compared to non-users (27.81% [n=240/863] vs 19.26% [n=42/218], respectively, OR=1.248 95% CI: 1.041, 1.509) and treatment return rate compared to non-users (46.00% [n=169/363] vs 31.37% [n=32/102] respectively, OR=1.339 95% CI: 1.092, 1.656). It was not associated with live birth rate per complete cycle.
Conclusion
The observed positive association between MediEmo use and live birth and treatment return rates suggests benefits to patients and clinics. Further research and replication using a randomised controlled trial design is warranted as is investment in development of digital tools for use during IVF treatment.
To explore the associations between the use of the MediEmo smartphone application and IVF live birth and treatment return rates.
Design
A three-year observational cohort study
Subjects
Patients undergoing IVF were classified as users if they used the medication or emotion features of the MediEmo. Patients who did not use the two key features or declined to use the app were classified as non-users.
Exposure
The use of the MediEmo smartphone application.
Main outcome measures
Outcomes of interest were rate of live birth per fresh index cycle, live birth per complete cycle and treatment return for a stimulated cycle of treatment within 12 months of the unsuccessful stimulated index cycle.
Results
A total 1081 patients were eligible to use MediEmo app, 863 were categorised as users and 218 as non-users. MediEmo use was associated with a higher live birth rate per index cycle compared to non-users (27.81% [n=240/863] vs 19.26% [n=42/218], respectively, OR=1.248 95% CI: 1.041, 1.509) and treatment return rate compared to non-users (46.00% [n=169/363] vs 31.37% [n=32/102] respectively, OR=1.339 95% CI: 1.092, 1.656). It was not associated with live birth rate per complete cycle.
Conclusion
The observed positive association between MediEmo use and live birth and treatment return rates suggests benefits to patients and clinics. Further research and replication using a randomised controlled trial design is warranted as is investment in development of digital tools for use during IVF treatment.
| Original language | English |
|---|---|
| Journal | F&S reports |
| Early online date | 10 Apr 2025 |
| DOIs | |
| Publication status | E-pub ahead of print - 10 Apr 2025 |